Parallel Bio

Cambridge, United States Founded: 2020 • Age: 6 yrs
Limited information available

About Parallel Bio

Parallel Bio is a company based in Cambridge (United States) founded in 2020.. Parallel Bio has raised $25.43 million across 3 funding rounds from investors including Refactor Capital, Y Combinator and AIX Ventures. The company has 6 employees as of December 31, 2022. Parallel Bio offers products and services including Immune Organoids Platform and AI Drug Discovery Service. Parallel Bio operates in a competitive market with competitors including Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn, among others.

  • Headquarter Cambridge, United States
  • Employees 6 as on 31 Dec, 2022
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Parallel Biosystems Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $25.43 M (USD)

    in 3 rounds

  • Latest Funding Round
    $21 M (USD), Series A

    Jun 12, 2025

  • Investors
  • Employee Count
    6

    as on Dec 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Parallel Bio

Parallel Bio offers a comprehensive portfolio of products and services, including Immune Organoids Platform and AI Drug Discovery Service. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Enables in-vitro testing of drugs using human immune replicas.

Uses AI to analyze immune data for faster drug candidate verification.

People of Parallel Bio
Headcount 1-10
Employee Profiles 7
Employee Profiles
People
Mary Clare McFadden
Director Of Talent Acquisition
People
Juliana L.
Co-Founder & CSO
People
Robert M. DiFazio
Co-Founder & CEO
People
Juliana L. Hilliard
Co-Founder & CSO

Unlock access to complete

Funding Insights of Parallel Bio

Parallel Bio has successfully raised a total of $25.43M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $21 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series A — $21.0M
  • First Round

    (01 Jun 2021)

  • Investors Count 9
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2025 Amount Series A - Parallel Bio Valuation AIX Ventures
Jan, 2023 Amount Seed - Parallel Bio Valuation Refactor Capital
Jun, 2021 Amount Seed - Parallel Bio Valuation Y Combinator
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Parallel Bio

Parallel Bio has secured backing from 9 investors, including venture fund and angel investors. Prominent investors backing the company include Refactor Capital, Y Combinator and AIX Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Angel
Investor Description Founded Year Domain Location
Seed and early-stage investments are made across US and India.
Founded Year Domain Location
Early-stage startups are accelerated via funding and educational programs.
Founded Year Domain Location
Venture capital is provided to AI-powered companies by AIX Ventures.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Parallel Bio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Parallel Bio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Parallel Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Parallel Bio

Parallel Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, InSphero, Pandorum, Vivodyne and Adapsyn, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Induced pluripotent stem cell-derived organoid models are developed for research.
domain founded_year HQ Location
Cell-based assays and 3D microtissues for drug screening are developed.
domain founded_year HQ Location
Regenerative medicine and 3D tissues are developed for therapeutic uses.
domain founded_year HQ Location
Developer of AI-based platform for lab-grown human tissues
domain founded_year HQ Location
Provider of computational tools for bacterial metabolomic and genomic data analysis
domain founded_year HQ Location
Scalable processes for organoid expansion are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Parallel Bio

Parallel Bio’s $4.3 Million Seed Funding
Globallegalchronicle3 years ago

Frequently Asked Questions about Parallel Bio

When was Parallel Bio founded?

Parallel Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Parallel Bio located?

Parallel Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Is Parallel Bio a funded company?

Parallel Bio is a funded company, having raised a total of $25.43M across 3 funding rounds to date. The company's 1st funding round was a Seed of $125K, raised on Jun 01, 2021.

How many employees does Parallel Bio have?

As of Dec 31, 2022, the latest employee count at Parallel Bio is 6.

What does Parallel Bio do?

Parallel Bio was founded in 2020 and is located in Cambridge, United States. The companys domain, parallel.bio, serves as its primary online identifier. Limited details are available concerning its industry sector, specific operations, or services provided. Further information on core activities remains undisclosed in public sources at this time.

Who are the top competitors of Parallel Bio?

Parallel Bio's top competitors include Newcells Biotech, InSphero and Vivodyne.

What products or services does Parallel Bio offer?

Parallel Bio offers Immune Organoids Platform and AI Drug Discovery Service.

Who are Parallel Bio's investors?

Parallel Bio has 9 investors. Key investors include Refactor Capital, Y Combinator, AIX Ventures, Marc Benioff, and Metaplanet.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available